<DOC>
	<DOCNO>NCT02452632</DOCNO>
	<brief_summary>The purpose study compare efficacy safety ASP1941 50mg daily combination metformin sitagliptin placebo combination metformin sitagliptin 24 week treatment period subject type 2 diabetes mellitus inadequate glycemic control metformin sitagliptin .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ASP1941 Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Metformin Sitagliptin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Subject diagnose type 2 diabetes mellitus . Subject HbA1c value 7.0 % 10.5 % visit 1 . Subject show FPG ( Fasting Plasma Glucose ) value less 270mg/dL . Subject show BMI 20.0 45.0 kg/m2 . Subject stable diet exercise program least 8 week prior study participation . Postmenopausal female surgically sterile female agree become pregnant . Subject type 1 diabetes mellitus . Subject proliferative diabetic retinopathy . Subject history clinically significant renal disease ( ) renovascular occlusive disease , nephrectomy , renal transplant . Subject significant dysuria cause neurogenic bladder benign prostatic hypertrophy etc . Subject symptomatic urinary tract infection genital infection . Subject chronic disease ( ) require continuous use systemic corticosteroid immunosuppressant . Subject cardiovascular disease cerebrovascular disease may affect administration ASP1941 safety assessment opinion investigator subinvestigator . Subject uncontrollable psychiatric disorder ( ) medication . Male subject willing use appropriate contraception study . Subject severe infection , serious trauma , perioperative subject . Subject malignant tumor history malignant tumor . Subject severe gastrointestinal disease , history operation serious gastrointestinal disease . Subject diabetic ketoacidosis . Subject lactic acidosis history lactic acidosis . Subject hepatitis carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , positive HIV1 and/or HIV2 . Subject history thyroid dysfunction acute pancreatitis . Subject weightloss program weightloss medication ( e.g . orlistat , phentermine/topiramate , lorcaserin ) within 12 week study participation . Subject history serious cardiac disease ( NYHA Class III IV ) , congestive heart failure , arrhythmia need medical treatment . Subject history cerebrovascular attack , unstable angina , myocardial infarction , angioplasty , within 52 week ( 364 day ) study participation . Subject uncontrollable severe hypertension , i.e. , systolic blood pressure high 180 mmHg diastolic blood pressure high 110mmHg measure sit position 5minute rest . Subject follow AST ALT value : AST : Male &gt; 100 U/L , Female &gt; 80 U/L ALT : Male &gt; 102.5 U/L , Female &gt; 82.5 U/L Subject follow serum creatinine value : Creatinine : Male &gt; 1.3 mg/dL , Female &gt; 1.2 mg/dL Subject estimate GFR value , &lt; 60 mL/min/1.73m2 .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>